Literature DB >> 11805215

The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels.

Dierk Thomas1, Bernd Gut, Gunnar Wendt-Nordahl, Johann Kiehn.   

Abstract

Fluoxetine is a commonly prescribed antidepressant compound. Its action is primarily attributed to selective inhibition of the reuptake of serotonin (5-hydroxytryptamine) in the central nervous system. Although this group of antidepressant drugs is generally believed to cause fewer proarrhythmic side effects compared with tricyclic antidepressants, serious concerns have been raised by case reports of tachycardia and syncopes associated with fluoxetine treatment. To determine the electrophysiological basis for the arrhythmogenic potential of fluoxetine, we investigated the effects of this drug on cloned human ether-a-go-go-related gene (HERG) potassium channels heterologously expressed in Xenopus oocytes using the two-microelectrode voltage-clamp technique. We found that fluoxetine blocked HERG channels with an IC(50) value of 3.1 microM. Inhibition occurred fast to open channels with very slow unbinding kinetics. Analysis of the voltage dependence of block revealed loss of inhibition at membrane potentials greater than 40 mV, indicating that channel inactivation prevented block by fluoxetine. No pronounced changes in electrophysiological parameters such as voltage dependence of activation or inactivation, or inactivation time constant could be observed, and block was not frequency-dependent. This is the first study demonstrating that HERG potassium channels are blocked by the selective serotonin reuptake inhibitor fluoxetine. We conclude that HERG current inhibition might be an explanation for the arrhythmogenic side effects of this drug.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11805215     DOI: 10.1124/jpet.300.2.543

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  46 in total

1.  Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries.

Authors:  Fabrizio De Ponti; Elisabetta Poluzzi; Alberto Vaccheri; Ulf Bergman; Lars Bjerrum; John Ferguson; Kerry J Frenz; Peter McManus; Ingrid Schubert; Gisbert Selke; Georgia Terzis-Vaslamatzis; Nicola Montanaro
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

Review 2.  Drug-induced long QT syndrome.

Authors:  Prince Kannankeril; Dan M Roden; Dawood Darbar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Effects of dapoxetine on cloned Kv1.5 channels expressed in CHO cells.

Authors:  Imju Jeong; Shin Hee Yoon; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-04-27       Impact factor: 3.000

4.  Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels.

Authors:  Dierk Thomas; Sven Kathofer; Wei Zhang; Kezhong Wu; Anna-Britt Wimmer; Edgar Zitron; Volker A W Kreye; Hugo A Katus; Wolfgang Schoels; Christoph A Karle; Johann Kiehn
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

5.  K2P channel gating mechanisms revealed by structures of TREK-2 and a complex with Prozac.

Authors:  Yin Yao Dong; Ashley C W Pike; Alexandra Mackenzie; Conor McClenaghan; Prafulla Aryal; Liang Dong; Andrew Quigley; Mariana Grieben; Solenne Goubin; Shubhashish Mukhopadhyay; Gian Filippo Ruda; Michael V Clausen; Lishuang Cao; Paul E Brennan; Nicola A Burgess-Brown; Mark S P Sansom; Stephen J Tucker; Elisabeth P Carpenter
Journal:  Science       Date:  2015-03-13       Impact factor: 47.728

6.  Escitalopram block of hERG potassium channels.

Authors:  Yun Ju Chae; Ji Hyun Jeon; Hong Joon Lee; In-Beom Kim; Jin-Sung Choi; Ki-Wug Sung; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-09-18       Impact factor: 3.000

7.  Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.

Authors:  James T Milnes; Olivia Crociani; Annarosa Arcangeli; Jules C Hancox; Harry J Witchel
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

8.  Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin.

Authors:  Daniel Scherer; Katharina von Löwenstern; Edgar Zitron; Eberhard P Scholz; Ramona Bloehs; Sven Kathöfer; Dierk Thomas; Alexander Bauer; Hugo A Katus; Christoph A Karle; Claudia Kiesecker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-05-06       Impact factor: 3.000

9.  Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone.

Authors:  Edgar Zitron; Claudia Kiesecker; Eberhard Scholz; Sonja Lück; Ramona Bloehs; Sven Kathöfer; Dierk Thomas; Johann Kiehn; Volker A W Kreye; Hugo A Katus; Wolfgang Schoels; Christoph A Karle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-29       Impact factor: 3.000

Review 10.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.